Skip to Content
Merck
All Photos(1)

Documents

D4407

Sigma-Aldrich

2-Deoxy-D-galactose

98%

Synonym(s):

2-Deoxy-D-lyxohexose

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C6H12O5
CAS Number:
Molecular Weight:
164.16
Beilstein:
1723333
EC Number:
MDL number:
UNSPSC Code:
12352201
PubChem Substance ID:
NACRES:
NA.22

Assay

98%

form

powder

optical activity

[α]20/D +59.7°, c = 2 in H2O

color

white to off-white

mp

107 - 110 °C ((225 - 230 °F))
107-110 °C (lit.)

SMILES string

OC[C@H]1OC(O)C[C@@H](O)[C@H]1O

InChI

1S/C6H12O5/c7-2-4-6(10)3(8)1-5(9)11-4/h3-10H,1-2H2/t3-,4-,5?,6-/m1/s1

InChI key

PMMURAAUARKVCB-DUVQVXGLSA-N

Looking for similar products? Visit Product Comparison Guide

General description

2-Deoxy-D-galactose is a glucose analog that shows a wide range of biological activities such as inhibition of glycolysis and thereby tumor growth, interference with the biosynthetic processing of glycoproteins, antiviral activity, and hepatotoxicity. It is being extensively studied as trapping agents for phosphate and uridylate in mammalian cells due to its ability to interfere in the phosphate and nucleotide metabolism.

Application


  • FUT1-mediated terminal fucosylation acts as a new target to attenuate renal fibrosis.: This research investigates the role of 2-deoxy-D-galactose in modulating terminal fucosylation processes, revealing potential therapeutic pathways for treating renal fibrosis and enhancing the understanding of kidney disease mechanisms (Luo et al., 2023).

  • 2-D-gal Targets Terminal Fucosylation to Inhibit T-cell Response in a Mouse Skin Transplant Model.: Highlights the immunomodulatory potential of 2-deoxy-D-galactose in transplant medicine, showing how it can inhibit T-cell responses and contribute to the success of skin grafts, pointing towards new immunosuppressive treatments (Mao et al., 2023).

  • Inhibition of Aberrant α(1,2)-Fucosylation at Ocular Surface Ameliorates Dry Eye Disease.: Explores the therapeutic effects of 2-deoxy-D-galactose in treating dry eye disease by modulating specific fucosylation pathways, potentially opening new avenues for ocular surface treatment strategies (Yoon et al., 2021).

Other Notes

To gain a comprehensive understanding of our extensive range of Monosaccharides for your research, we encourage you to visit our Carbohydrates Category page.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

T Platt
Molecular and cellular biology, 4(5), 994-996 (1984-05-01)
Analysis of 400 independent spontaneous mutations conferring 2-deoxygalactose resistance upon cells constitutive for the galactose pathway suggests that toxicity is due to 2-deoxygalactose-1-phosphate. Selection for and against growth on galactose in the same strain is now possible; application to systems
2-Deoxy-D-galactose impairs the fucosylation of glycoproteins of rat liver and Morris hepatoma.
R Büchsel et al.
European journal of biochemistry, 111(2), 445-453 (1980-10-01)
J A Gorman et al.
Genetics, 129(1), 19-24 (1991-09-01)
A technique which has the potential to allow repeated use of the same selectable marker to create gene disruptions in Candida albicans has been developed. In this approach, originally described for Saccharomyces cerevisiae, the selectable marker is flanked by direct
S Bullock et al.
Journal of neurochemistry, 54(1), 135-142 (1990-01-01)
The interaction of the amnesic agent 2-deoxygalactose with fucose incorporation into glycoproteins in day-old chick forebrain has been studied with the aim of identifying glycoproteins whose synthesis is modified during memory formation. 2-Deoxygalactose inhibited total exogenous [14C]fucose incorporation into the
R Jork et al.
Pharmacology, biochemistry, and behavior, 25(6), 1137-1144 (1986-12-01)
The intraventricular injection of 2-deoxy-D-galactose led to a dose- and time-dependent decrease in the fucosylation of hippocampal glycoproteins in rats whereas the incorporation of 3H-N-acetyl-glucosamine was not influenced. This effect is not related to an interference with fucose activating or

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service